Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.55 |
| ▸ | ENPEP | Q07075 | 11/20 | 0.37 |
| ▸ | ANPEP | P15144 | 4/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cysteine SCHEMBL4864416 | 1.00 | PTGS1 (0.55) | PTGS1SLC7A11ENPEPANPEPCA4 | |
| Cysteine SCHEMBL492744 | 0.95 | PTGS1 (0.56) | PTGS1SLC7A11ENPEPANPEPMMP2 | |
| Cysteine SCHEMBL1072972 | 0.94 | PTGS1 (0.55) | PTGS1SLC7A11ENPEPANPEPCA4 | |
| Cysteine SCHEMBL8378977 | 0.94 | PTGS1 (0.55) | PTGS1SLC7A11ENPEPANPEPCA4 | |
| Cysteine SCHEMBL17473902 | 0.94 | — | — | |
| Cysteine SCHEMBL23903319 | 0.94 | PTGS1 (0.55) | PTGS1SLC7A11ENPEPANPEPCA4 | |
| Cysteine SCHEMBL5046068 | 0.94 | — | — | |
| Cysteine SCHEMBL16194528 | 0.94 | — | — | |
| Cysteine SCHEMBL8501902 | 0.94 | PTGS1 (0.55) | PTGS1SLC7A11ENPEPANPEPCA4 | |
| Cysteine SCHEMBL5307589 | 0.94 | PTGS1 (0.55) | PTGS1SLC7A11ENPEPANPEPCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375246-B2 | Sulfhydral containing compounds and methods of using the same | REGENESIS BIOREMEDIATION PRODUCTS INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-20050148712-A1 | Polyol esters of sulfhydryl carboxylic acids; treating water and water-containing soils contaminated with metal | FARONE WILLIAM A (US) | 2005-07-07 | — | — | US | disclosed |
| US-6846947-B2 | Sulfhydral containing compounds and methods of using same | REGENESIS BIOREMEDIATION PRODUCTS, INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-20040157316-A1 | Sulfhydral containing compounds and methods of using same | REGENESIS | 2004-08-12 | — | — | US | disclosed |
| US-20040158095-A1 | Sulfhydral containing compounds and methods of using same | REGENESIS, INC. | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158095-A1 | Sulfhydral containing compounds and methods of using same | TST, QSOX1, CTH | PTGS1 285/4885SLC7A11 90/4885ENPEP 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.